التفاصيل البيبلوغرافية
| العنوان: |
Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report |
| المؤلفون: |
Thomas, Quentin Dominique, Basse, Clémence, Luporsi, Marie, Girard, Nicolas |
| المصدر: |
Frontiers in Oncology ; volume 11 ; ISSN 2234-943X |
| بيانات النشر: |
Frontiers Media SA |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers (Publisher - via CrossRef) |
| مصطلحات موضوعية: |
Cancer Research, Oncology |
| الوصف: |
Metastatic thymic carcinomas have a poor prognosis. Pembrolizumab, an anti-PD-1 antibody, has recently been evaluated for patients with metastatic thymic carcinomas progressing after at least one line of platinum-based chemotherapy. The antitumor activity of immunotherapy appears to be promising for these patients and pembrolizumab in monotherapy is actually a treatment option in second metastatic line. To the best of our knowledge, we report the first case of a patient treated for metastatic thymic adenocarcinoma with a combination of chemotherapy–immunotherapy. The patient is a 46-year-old man with metastatic thymic adenocarcinoma treated in third metastatic line with a combination of pembrolizumab plus platinum-based chemotherapy with a very good metabolic tumor response. He had a progression-free survival of 7.9 months and did not experience any severe side effects related to pembrolizumab. The association of immunotherapy and chemotherapy, as in non-small cell and small cell lung cancers, could be of interest for future therapeutic trials evaluating the survival of patients with metastatic thymic carcinoma. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| DOI: |
10.3389/fonc.2021.814544 |
| DOI: |
10.3389/fonc.2021.814544/full |
| الإتاحة: |
https://doi.org/10.3389/fonc.2021.814544Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.685E747D |
| قاعدة البيانات: |
BASE |
